Respiratory disease

Global Mucus Clearance Devices Market Review 2017-2019 and Forecast to 2027 - Supportive Regulatory Environment for the Development & Sale of Mucus Clearance Devices Drives the Market - ResearchAndMarkets.com

Wednesday, November 20, 2019 - 3:35pm

The global mucus clearance devices market is expected to expand at a CAGR of 7.3% from 2019 to 2027.

Key Points: 
  • The global mucus clearance devices market is expected to expand at a CAGR of 7.3% from 2019 to 2027.
  • Constant exposure to lung irritants and concomitant respiratory infections are responsible for the occurrence of chronic respiratory illness worldwide.
  • Chronic obstructive pulmonary disease is the largest indication segment for mucus clearance devices market.
  • North America accounts for a market share of 35.1% and is the dominating regional segment for mucus clearance devices market.

H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Generation Cellular Therapy for COPD

Monday, November 18, 2019 - 1:00pm

The new funding will be used to advance the companys development of industry-leading medical treatments for chronic lung diseases such as COPD.

Key Points: 
  • The new funding will be used to advance the companys development of industry-leading medical treatments for chronic lung diseases such as COPD.
  • It is estimated that 24 million people in the U.S. have COPD, an umbrella term that encompasses many other conditions, including emphysema and chronic bronchitis.
  • According to the CDC , more than 140,000 Americans die from this condition each year and there is currently no cure.
  • H-CYTE recently entered into a long-term agreement with Rion that will enable H-CYTE to develop proprietary biologics for treatment of COPD.

resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

Friday, November 15, 2019 - 12:00pm

The primary endpoint of the trial was the reduction in the percentage of subjects with clinically symptomatic respiratory illness, defined as illness associated with a respiratory tract infection, or RTI, based on prespecified diagnostic criteria, with or without laboratory confirmation of a pathogen.

Key Points: 
  • The primary endpoint of the trial was the reduction in the percentage of subjects with clinically symptomatic respiratory illness, defined as illness associated with a respiratory tract infection, or RTI, based on prespecified diagnostic criteria, with or without laboratory confirmation of a pathogen.
  • The PROTECTOR 1 trial included 1024 patients who were randomized 1:1 to receive RTB101 or placebo administered once daily for 16 weeks.
  • resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Global Asthma Spacers Market 2019-2023 | Evolving Opportunities with ALLERGAN & Cipla | Technavio

Wednesday, November 13, 2019 - 11:30am

View the full release here: https://www.businesswire.com/news/home/20191113005363/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191113005363/en/
    Technavio has announced its latest market research report titled global asthma spacers market 2019-2023.
  • Also, the increase in online retail is anticipated to further boost the growth of the asthma spacers market.
  • The growing demand for respiratory care is expected to drive the growth of the global asthma spacers market.
  • Allergy, pollution, and smoking can result in several respiratory diseases such as obstructive airway diseases like asthma, COPD, and cystic fibrosis.

Breath Biopsies: A Revolutionary Approach for Noninvasive Diagnosis - 2019 Market Research Report

Tuesday, November 12, 2019 - 5:30pm

DUBLIN, Nov. 12, 2019 /PRNewswire/ -- The "Breath Biopsies: A Revolutionary Approach for Noninvasive Diagnosis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 12, 2019 /PRNewswire/ -- The "Breath Biopsies: A Revolutionary Approach for Noninvasive Diagnosis" report has been added to ResearchAndMarkets.com's offering.
  • In the future, a variety of conditions may be diagnosed with a simple breath test.
  • Researchers are looking beyond blood tests and solid/liquid biopsies to find other sources of information to diagnose disease.
  • Assessment of the role of breath biopsy in drug development, diagnosis, and treatment of respiratory diseases, cancer, metabolic disorders, and CNS diseases

Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

Thursday, November 7, 2019 - 9:05pm

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2019 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2019 and provided a business update.
  • Presented efficacy and safety results from IMPALA, a Phase 3 study evaluating Molgradex for the treatment of aPAP, at the European Respiratory Society (ERS) International Congress.
  • As of September 30, 2019, Savara had a carrying value of its debt of approximately $25.0 million and had cash, cash equivalents, and short-term investments of approximately $106.3 million.
  • Savara management will host a conference call/webcast with accompanying slides at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).

PulmOne Now Offering FeNO by NIOX® with Its MiniBox+™ Complete Pulmonary Function Testing System

Thursday, November 7, 2019 - 2:00pm

The MiniBox+, a desktop, cabinless device, is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients, as recommended by the American Thoracic Society (ATS).

Key Points: 
  • The MiniBox+, a desktop, cabinless device, is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients, as recommended by the American Thoracic Society (ATS).
  • Integrating the NIOX VERO asthma management system expands the testing capabilities of the MiniBox+, enabling physicians to detect and treat an even wider range of respiratory disorders.
  • "We are delighted to offer our customers the world's leading FeNO system as a new enhancement to the MiniBox+.
  • NIOX VERO cannot be used with infants or by children under the age of 7, as measurement requires patient cooperation.

Blue Cross and Blue Shield of Texas Awards More Than $1.6 million To Fight Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease

Monday, November 4, 2019 - 6:05pm

The strategy has proven empirically successful in decreasing emergency room visits, while increasing primary doctor and specialist visits, according to BCBSTX claims data.

Key Points: 
  • The strategy has proven empirically successful in decreasing emergency room visits, while increasing primary doctor and specialist visits, according to BCBSTX claims data.
  • American Lung Association : Leadingthe fight for healthy lungs and air as well as on eliminating tobacco use and related lung disease.
  • Texas CASA : To support statewide child advocacy programs that provide a safe and positive future for all Texas children.
  • Health Care Service Corporation is a Mutual Legal Reserve Company and an Independent Licensee of the Blue Cross and Blue Shield Association.

Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019

Friday, October 18, 2019 - 9:30pm

Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.

Key Points: 
  • Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.
  • Altavant is currently testing this mechanism of action in the ELEVATE1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with pulmonary arterial hypertension (PAH).
  • Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases with an initial focus on pulmonary arterial hypertension (PAH).
  • Rodatristat ethyl is currently being investigated in the ELEVATE1 Phase 2a study in patients with PAH.

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

Tuesday, October 15, 2019 - 7:00am

LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.

Key Points: 
  • LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.
  • Kathleen Rickard, M.D., CMO at Verona Pharma, will expand on symptom data first announced by the Company on March 26, 2018 where ensifentrine produced clinically and statistically significant improvements in lung function as well as significant and progressive improvements in COPD symptoms.
  • Oral Presentation/Poster: Poster E1037 Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea
    COPD is a progressive and life-threatening respiratory disease without a cure.
  • Nebulized ensifentrine (RPL554) has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharmas prior Phase 2 clinical studies in patients with moderate-to-severe COPD.